Search clinical trials for: Sitaxsentan

Total 22 results

Pfizer

Terminated

Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Hypertension, Pulmonary

Japan
Pfizer

Terminated

A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients

Hypertension, Pulmonary

Japan
Pfizer

Terminated

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3)

Pulmonary Arterial Hypertension

United States, Netherlands, Canada, Belgium, France, Germany, Italy, Spain, United Kingdom, Australia, Poland, Austria, Brazil, Israel, Argentina, Mexico
Institut National de la Santé Et de la Recherche...

Terminated

Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma (Sitax)

Effect of Sitaxsentan on Airway Remodeling in Severe Asthma

France
Pfizer

Terminated

A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin (PROSE)

Pulmonary Arterial Hypertension

Belgium, Germany, France
Pfizer

Completed

Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension
Pfizer

Completed

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

Healthy

United States
Pfizer

Terminated

A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses

Pulmonary Arterial Hypertension

Singapore
Pfizer

Completed

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery (FCAD02)

Cardiac Surgery Subjects | Subjects Undergoing CABG and/or Cardiac Valve Replacement

United States
VA Office of Research and Development
Medical University of South Carolina

Completed

Proteolytic Enzyme Induction Within the Human Myocardial Interstitium

Heart Disease

United States
ICOS-Texas Biotechnology
ICOS Corporation; Texas Biotechnology Corporation

Unknown

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States, Canada
Encysive Pharmaceuticals

Completed

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States
Pfizer

Terminated

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Bulgaria, Argentina, Chile, China, Colombia, Costa Rica, Czech Republic, Dominican Republic, Guatemala, India, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, South... and more
Pfizer

Terminated

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Romania, Ukraine
Pfizer

Withdrawn

Drug Interaction Between Ritonavir And Sitaxsentan

Pulmonary Arterial Hypertension
Pfizer

Terminated

Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States, Bulgaria, Argentina, Chile, China, Colombia, Czech Republic, India, Malaysia, Mexico, Peru, Romania, Russian Federation, Serbia, South Africa, Thailand, Turkey, Ukraine
Pfizer

Completed

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

Diastolic Heart Failure

United States, Canada
West Penn Allegheny Health System
Johns Hopkins University; University of Colorado, Denver; Massachusetts General... and other collaborators

Withdrawn

Pharmacogenomics in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension | PAH WHO Group I

United States
University of Edinburgh
Encysive Pharmaceuticals

Completed

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

Pulmonary Arterial Hypertension | Vasodilation | Vasoconstriction

United Kingdom
Pfizer

Withdrawn

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Pulmonary Arterial Hypertension
Pfizer

Completed

Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects (FCRD01)

Chronic Kidney Disease

United Kingdom
University of Edinburgh
Encysive Pharmaceuticals

Unknown

Sitaxsentan in Proteinuric Chronic Kidney Disease

Proteinuria | Chronic Kidney Disease | Blood Pressure

United Kingdom

Search clinical trials for: Sitaxsentan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations